Ras Regulates SCF\(^{\beta}\)-TrCP Protein Activity and Specificity via Its Effector Protein NORE1A*

Received for publication, July 3, 2014, and in revised form, September 12, 2014 Published, JBC Papers in Press, September 12, 2014, DOI 10.1074/jbc.M114.594283

M. Lee Schmidt‡, Howard Donninger§, and Geoffrey J. Clark¶

From the Molecular Targets Group, James Graham Brown Cancer Center, Departments of ‡Biochemistry and Molecular Biology, §Medicine, and ¶Pharmacology and Toxicology, University of Louisville, Louisville, Kentucky 40202

Background: NORE1A is a Ras effector with a poorly defined function.

Results: NORE1A forms a direct, Ras-regulated complex with \(\beta\)-TrCP and activates the SCF\(^{\beta}\)-TrCP ubiquitin ligase complex to promote \(\beta\)-catenin degradation.

Conclusion: Ras controls the activity and specificity of SCF\(^{\beta}\)-TrCP via NORE1A.

Significance: We identify a novel Ras signaling pathway, defective in many tumors, that allows Ras to control specific protein stability.

Ras is the most frequently activated oncogene found in human cancer, but its mechanisms of action remain only partially understood. Ras activates multiple signaling pathways to promote transformation. However, Ras can also exhibit a potent ability to induce growth arrest and death. NORE1A (RASSF5) is a direct Ras effector that acts as a tumor suppressor by promoting apoptosis and cell cycle arrest. Expression of NORE1A is frequently lost in human tumors, and its mechanism of action remains unclear. Here we show that NORE1A forms a direct, Ras-regulated complex with \(\beta\)-TrCP, the substrate recognition component of the SCF\(^{\beta}\)-TrCP ubiquitin ligase complex. This interaction allows Ras to stimulate the ubiquitin ligase activity of SCF\(^{\beta}\)-TrCP toward its target \(\beta\)-catenin, resulting in degradation of \(\beta\)-catenin by the 26 S proteasome. However, the action of Ras/NORE1A/\(\beta\)-TrCP is substrate-specific because IκB, another substrate of SCF\(^{\beta}\)-TrCP, is not sensitive to NORE1A-promoted degradation. We identify a completely new signaling mechanism for Ras that allows for the specific regulation of SCF\(^{\beta}\)-TrCP targets. We show that the NORE1A levels in a cell may dictate the effects of Ras on the Wnt/\(\beta\)-catenin pathway. Moreover, because NORE1A expression is frequently impaired in tumors, we provide an explanation for the observation that \(\beta\)-TrCP can act as a tumor suppressor or an oncogene in different cell systems.

Genetic mutations leading to activated forms of the Ras oncogene can be detected in almost one-third of human cancers (1). When activated, the Ras oncoprotein drives growth and transformation by binding and activating multiple effectors that stimulate multiple signaling pathways. Two of the best characterized cascades are the Raf and PI3K effector pathways (2). However, Ras can also impact other signaling pathways important to proliferation and development, such as the Wnt/\(\beta\)-catenin signaling pathway (3). The interaction of the Ras and the Wnt/\(\beta\)-catenin signaling pathways is quite complex and appears to occur at multiple levels (4–6). An interesting dichotomy exists because Ras has been reported to exhibit both positive and negative effects on the pathway (4–6). Moreover, although synergistic activation of transformation by Ras and Wnt/\(\beta\)-catenin has been reported, other reports have identified an antagonistic role in transformation (5, 6). How Ras impacts the Wnt/\(\beta\)-catenin pathway is still not fully understood, nor is the balance of cellular factors that dictate whether a net positive or negative effect is observed for Ras on Wnt/\(\beta\)-catenin pathway signaling.

In the canonical Wnt/\(\beta\)-catenin pathway, \(\beta\)-catenin is the terminal executor, serving as both a nuclear transcriptional coregulator and key component of adherens junctions (7). In the absence of Wnt ligand signaling, a multiprotein complex consisting of APC, Axin, and GSK-3\(\beta\) phosphorylates \(\beta\)-catenin. This phosphorylation is necessary for the binding of \(\beta\)-TrCP, the substrate recognition component of the SCF\(^{\beta}\)-TrCP ubiquitin ligase complex. SCF\(^{\beta}\)-TrCP-mediated ubiquitination of \(\beta\)-catenin results in its rapid degradation by the 26 S proteasome (8). Upon Wnt signaling, the phosphorylation complex is destabilized by Disheveled family proteins, allowing for unphosphorylated \(\beta\)-catenin levels to quickly increase in the cytoplasm and translocate to the nucleus. Nuclear \(\beta\)-catenin functions as a cofactor for transcription factors of the TCF/LEF family, modulating genes involved in growth and survival (9).

Although cells constitutively synthesize \(\beta\)-catenin to maintain a ready response to incoming Wnt signaling, the high turnover rate of \(\beta\)-catenin via the SCF\(^{\beta}\)-TrCP ubiquitin ligase complex maintains homeostasis (10). Mechanistic corruption in the regulatory mechanism of \(\beta\)-catenin has been described in many human cancers, and mutated forms of \(\beta\)-catenin that cannot be ubiquitinated by the SCF\(^{\beta}\)-TrCP ubiquitin ligase are oncogenic (9). By enhancing down-regulation of \(\beta\)-catenin, \(\beta\)-TrCP can serve as a tumor suppressor (11). However, the situation is more complex because \(\beta\)-TrCP has also been reported to have oncogenic potential in some situations (12, 13). This may be due to its role in degrading non-\(\beta\)-catenin targets such as Claspin (14).
Paradoxically, activated forms of Ras are not only powerfully transforming but can also act as powerful stimulators of cell death pathways (15, 16). In part, Ras-induced cell death appears to be mediated by members of the RASSF family of tumor suppressors, which bind Ras and serve as death effectors (16). NORE1A (RASSF5) was the first member of the RASSF family to be identified (17). It connects Ras to the pro-apoptotic Hippo pathway, but this does not seem to be essential for its tumor suppressor function. It also modulates p53 (18, 19), which may explain its ability to promote cell cycle arrest. NORE1A is expressed in most normal tissues, but its expression is lost in many tumors because of epigenetic inactivation or deregulated proteolysis (18, 20). NORE1A is a bona fide tumor suppressor because a hereditary genetic defect in NORE1A predisposes the human carriers to kidney cancer (21). However, the biological functions of the Ras/NORE1A interaction remain mostly uncharacterized.

We identified a direct interaction between NORE1A and β-TrCP in a yeast two-hybrid screen. This suggests that either NORE1A is a substrate for SCFβ-TrCP or, more interestingly, might connect Ras to the control of the complex. Because SCFβ-TrCP modulates the Wnt/β-catenin pathway by targeting β-catenin for degradation by the proteasome (11), NORE1A might serve to link Ras to the control of β-catenin.

We sought to determine the role of NORE1A in the control of the SCFβ-TrCP ubiquitin ligase and Wnt/β-catenin signaling. We show that the binding of NORE1A to β-TrCP is Ras-regulated and that it allows Ras to stimulate the activity of SCFβ-TrCP toward β-catenin.

The activation of the SCFβ-TrCP ubiquitin ligase complex by Ras/NORE1A is substrate-specific because NORE1A had no effect on SCFβ-TrCP substrate IκB. Moreover, NORE1A-deficient lung tumor cells exhibit enhanced steady-state levels of β-catenin and resist the growth inhibitory effects of β-TrCP. Therefore, the cellular levels of NORE1A may dictate how Ras modulates β-catenin and determine the substrate profile of the SCFβ-TrCP ubiquitin ligase. β-TrCP has been reported to be an oncogene and a tumor suppressor in different cell systems. The levels of NORE1A may dictate the ultimate activity of β-TrCP in a cell.

**EXPERIMENTAL PROCEDURES**

**Molecular Biology—**GFP-β-catenin was generated by PCR amplification of the human β-catenin cDNA (Addgene, catalog no. 16828) (22). The PCR product was TOPO-cloned into pGEM-T-Easy (Promega) and subcloned into pEGFP-C1 (Clontech) using BamHI and SalI restriction enzymes. β-TrCP1 was obtained from Addgene (catalog no. 4489) and cloned into enhanced GFP in a similar manner. Dominant negative β-TrCP1 was a gift from Tianyan Gao (University of Kentucky). Full-length human NORE1A cDNA was obtained from Origene (Rockville, MD), amplified, and subcloned using BglII/EcoRI into a BamHI/EcoRI restriction digest of pCDNA3 (Invitrogen) containing an in-frame 5′ HA tag (23, 24). We developed a triple point mutant of NORE1A, mutating the 92–94 residues from Arg to Ala using a PCR-based approach. Activated Ras has been described previously (25). NORE1A shRNA constructs (RHS4531-EG83593) were obtained from Open Biosystems (Rockford, IL). pGL3-BAR-Luc was a gift from Randall Moon (University of Washington, WA). The TK-Renilla luciferase plasmid was obtained from Promega (Madison, WI).

**Antibodies—**Anti-GFP (Santa Cruz Biotechnology, catalog no. SC-9996), anti-HA (Covance, catalog no. MMS-101P), anti-FLAG (Sigma-Aldrich, St. Louis MO, catalog no. F1804), anti-β-TrCP (Cell Signaling Technology, catalog no. 4394), anti-β-catenin (Cell Signaling Technology, catalog no. 8814), anti-phospho-β-catenin (Cell Signaling Technology, catalog no. 9561), rabbit polyclonal anti-NORE1A (19), and secondary antibodies were from Amersham Biosciences.

**Cell Culture and Transfections—**Cells were obtained from the ATCC. HEK-293 cells were grown in DMEM supplemented with 10% FBS. HEK-293 NF6K-B-luciferase cells were provided by Howard Donninger (University of Louisville, KY). NCI-H1299 cells were grown in RPMI medium with 10% FBS. Cells were transfected using jetPRIME® (Polyplus) transfection reagent. In the β-catenin stability studies, the proteasome was inhibited using MG132 (Sigma-Aldrich) at a final concentration of 5 μM and cycloheximide (Sigma-Aldrich) at a final concentration of 10 μM. Cell selections were performed in 500 μg/ml G418 (Sigma). FTI-277 was obtained from Calbiochem (La Jolla, CA).

**Immunoprecipitation and Western Blotting—**Cellular lysates for immunoprecipitation were prepared using a modified radioimmune precipitation assay buffer (50 mM Tris-HCl (pH 7.4), 200 mM NaCl, and 1% Nonidet P-40). Precleared lysate was incubated with GFP-Trap® beads (Allele Biotech, San Diego, CA) or with primary antibody or control IgG, followed by protein A/G beads (eBioscience), and washed with lysis buffer. Proteins were run on a 4–15% Tris-glycine gel (Bio-Rad) and transferred to 0.2 μm nitrocellulose (Bio-Rad). Blots were developed using West Pico enhanced ECL (Pierce) or West Femto enhanced ECL (Pierce).

**Luciferase Assays—**Dual luciferase assays were performed using reagents from the Promega Dual-Luciferase assay kit (catalog no. E1960). Cells were transfected for 24 h before lysis and reading using a Luminat LB 9507 from Berthold Technologies.

**RESULTS**

**NORE1A Forms a Direct, Endogenous, Ras-regulated Complex with β-TrCP—**β-TrCP is the substrate recognition component of the SCFβ-TrCP ubiquitin ligase. It is expressed as two closely related isoforms, β-TrCP1 and β-TrCP2. A yeast two-hybrid screen (Myriad Genetics, Salt Lake City, UT) using full-length NORE1A as bait identified β-TrCP1 as a potential direct binding partner. To determine whether this result was physiologival, we immunoprecipitated lysates from MCF10A cells for NORE1A and immunoblotted them for the presence of β-TrCP. Fig. 1A shows that NORE1A and β-TrCP could be detected in an endogenous complex. Further studies were then performed using exogenously expressed proteins. HEK-293 cells were cotransfected with expression constructs for NORE1A and β-TrCP1. The cells were then lysed and immunoprecipitated for β-TrCP1 and immunoblotted for NORE1A. The proteins could be coimmunoprecipitated (Fig. 1B).
NORE1A is a Ras effector protein. Consequently, we examined the role of Ras in the interaction between NORE1A and β-TrCP1 in similar experiments. The presence of activated H-Ras in the cotransfection enhanced the association between NORE1A and β-TrCP1 proteins (Fig. 1C). These blots were underexposed in comparison with the blots in Fig. 1B.

NORE1A Promotes β-Catenin Degradation via β-TrCP—Because β-TrCP is the substrate recognition component of the major ubiquitin ligase complex regulating protein levels of β-catenin (8), we examined the effects of NORE1A expression on β-catenin protein stability using transient transfections performed in HEK-293 cells. Coexpression of NORE1A suppressed the expression of β-catenin to subdetectable levels. This effect was largely blocked by the 26 S proteasome inhibitor MG132 (Fig. 2A). To further support the MG132 experiment, the transient transfections of NORE1A and β-catenin were repeated in HEK-293 cells. 24 h post-transfection, the cells were treated with cycloheximide. Dishes were lysed over a time course of 24 h, and samples were examined by Western blot analysis. The results confirmed that NORE1A was acting at a protein stability level (Fig. 2B). To determine whether NORE1A and β-TrCP1 synergize to promote the degradation of β-catenin, we partially inhibited the proteasome by adding low levels of MG132 for 6 h. Under these conditions, the ability of both NORE1A and β-TrCP1 to suppress β-catenin expression was impaired rather than abolished. This allowed us to detect a synergistic reduction in β-catenin levels when NORE1A and β-TrCP1 were transfected together (Fig. 3A). Furthermore, a
Ras Regulates β-TrCP Activity via NORE1A

To determine whether the effect of NORE1A on SSCPβ-TrCP is a general activation or a specific activation toward a particular subset of targets, a second degradation target of β-TrCP, IκB (30), was chosen for analysis. HEK-293 cells were transfected with expression constructs for IκB, β-catenin, and NORE1A. Western blot analysis of the protein levels showed that, although IκB levels remained nearly identical in the presence of NORE1A, NORE1A suppressed β-catenin protein levels more than the cells stably transfected with shRNA and assayed for the levels of endogenous β-catenin protein. β-catenin was elevated in the shRNA-transfected cells but not in the scrambled shRNA-transfected cells (Fig. 4C).

NORE1A Differentially Regulates β-TrCP Targets—To determine whether the effect of NORE1A on SCβ-TrCP is a general activation or a specific activation toward a particular subset of targets, a second degradation target of β-TrCP, IκB (30), was chosen for analysis. HEK-293 cells were transfected with expression constructs for IκB, β-catenin, and NORE1A. Western blot analysis of the protein levels showed that, although IκB levels remained nearly identical in the presence of NORE1A, NORE1A suppressed β-catenin (Fig. 5A). IκB is a negative regulator of NFκB (30). If NORE1A promotes its degradation, we should expect NFκB signaling to increase. Luciferase assays using HEK-293 cells stably transfected with an NFκB luciferase reporter showed that NORE1A does not promote the activation of NFκB (Fig. 5B).

NORE1A Levels Dictate the Biological Activity of β-TrCP—β-TrCP has a range of targets and can act as an oncogene or a tumor suppressor, depending upon the particular cellular milieu (11–14). The cofactors determining whether the net effect on growth of β-TrCP is positive or negative are not known. To determine whether NORE1A may be one of these factors, we transfected the NORE1A ± NCI-H1299 cell system with β-TrCP and selected for the marker carried by the β-TrCP construct. Fig. 6A shows that β-TrCP was highly growth-inhibitory in the NORE1A-positive cells but only

dominant negative form of β-TrCP (26) blocked NORE1A-mediated degradation of β-catenin (Fig. 3A).

To examine the effects of Ras on the system, we included activated H-Ras in the transfections, again with attenuation of the proteasome with low levels of MG132. Activated Ras enhances NORE1A activity against β-catenin (Fig. 3B). As further support for the role of Ras in directly modifying the action of NORE1A, we included a NORE1A point mutant that is defective for Ras binding in the assay (NORE1ARAMUT) (27). This experiment showed that the effects of Ras were due to its interaction with NORE1A (Fig. 3B).

NORE1A appears to regulate β-catenin protein levels through the proteasome by interacting with the ubiquitin ligase, β-TrCP. If this is indeed the mechanism of action, it would require β-catenin to be polyubiquitinated by β-TrCP, which would mark it for proteasomal degradation. To confirm this, HEK-293 cells were transfected with expression constructs for NORE1A and GFP-β-catenin along with a HA-tagged ubiquitin and treated with MG132. Incorporation of ubiquitin into GFP-β-catenin could be detected (Fig. 3C).

NORE1A Suppresses β-Catenin Signaling—Active β-catenin translocates to the nucleus, where it binds the transcriptional repressors TCF/LEF, thereby activating specific gene transcription. An artificial promoter sequence linked to the luciferase gene has been developed as a transcriptional reporter for β-catenin activity (28). This reporter, containing a β-catenin activation region (BAR-Luc), was cotransfected with an expression construct for β-catenin and a Renilla luciferase internal control into a matched pair of NCI-H1299 cells stably transfected with vector or NORE1A expression vector. The NORE1A-expressing cells showed reduced β-catenin activity (Fig. 4A).

Loss of NORE1A expression enhances steady-state levels of β-Catenin—The above results suggest that the loss of NORE1A that is so frequently found in human tumors should uncouple Ras from the negative regulation of β-catenin. Therefore, the levels of β-catenin in a Ras-driven tumor cell should inversely correlate with NORE1A expression. To test this hypothesis, we examined the levels of endogenous β-catenin in the NCI-H1299 NORE1A ± matched pair. These cells carry an activated Ras mutation and undetectable levels of endogenous NORE1A (29). Fig. 4B shows that the NORE1A-negative cells exhibited higher levels of endogenous β-catenin than the cells stably transfected with NORE1A. As further confirmation, we transfected HEK-293 cells with shRNA constructs against NORE1A and assayed for the levels of endogenous β-catenin protein. β-catenin was elevated in the shRNA-transfected cells but not in the scrambled shRNA-transfected cells (Fig. 4C).

FIGURE 3. A, HEK-293 cells were transfected with expression constructs for NORE1A, β-catenin (β-cat), β-TrCP1, and a dominant negative β-TrCP (ΔFBOX) that is unable to ubiquitinate target substrates. Low levels of MG132 were added to partially inhibit the 26 S proteasome and reveal differences between weak and strong activity. B, Immunoblot; Vec, vector; β, HEK-293 cells were transfected with expression constructs for NORE1A, a NORE1A mutant unable to bind to Ras (RAMUT), β-catenin, and activated H-Ras. Relative levels of β-catenin were assayed by immunoblot analysis. Actin served as a loading control. C, HEK-293 cells were cotransfected with expression constructs for NORE1A, β-catenin, and a HA-tagged ubiquitin. 24 h post-transfection, the cells were lysed and analyzed by Western blotting for HA incorporation into GFP-β-catenin (~120 kDa).
weakly inhibitory in the NORE1A-negative cells. The quantification is shown in Fig. 6B.

A key node in the Regulation of β-Catenin via Ras—Ras has been reported to exhibit both negative and positive effects on β-catenin protein levels (31, 32). The factors that determine the net effect of Ras on β-catenin are not clear. To determine whether NORE1A dictates the effects of Ras on β-catenin, we treated the NCI-NCI-H1299 NORE1A cell system with a farnesyl transferase inhibitor (FTI)2 that inactivates Ras (33). NCI-H1299 cells contain an activated form of Ras, which allowed us to examine the effects of endogenous Ras activation on endogenous β-catenin expression in a NORE1A-positive or -negative background. A “normal” cell is positive for NORE1A expression and does not have an activated Ras signaling pathway. The levels of β-catenin under these circumstances are shown in the fourth column of Fig. 7B. In the presence of a competent activated Ras (no FTI) in these NORE1A-positive cells, the levels of β-catenin go down (Fig. 7B, second column). However, when we remove the FTI from NORE1A-negative cells, we observed that the levels of β-catenin increased (Fig. 7B, first column) relative to the levels in normal cells (Fig. 7B, fourth column). Therefore, the presence or absence of NORE1A may dictate the effects of Ras, positive or negative, on β-catenin protein levels.

DISCUSSION

NORE1A binds activated Ras and serves as a proapoptotic Ras effector (18, 19). Furthermore, NORE1A suppresses tumor cell growth and is frequently inactivated in human tumors, and its inactivation is implicated in a hereditary cancer syndrome (16, 21, 23). Therefore, it is likely to serve as an important human tumor suppressor. NORE1A binds to the MST kinases and may connect Ras to the proapoptotic Hippo signaling pathway (18). However, deletion mutants of NORE1A that cannot interact with MST kinases retain the ability to inhibit cell growth and suppress the tumorigenic phenotype (34). Therefore, unknown tumor suppressor pathways independent of the classic Hippo pathway must also be modulated by NORE1A. β-TrCP is the substrate recognition component for the
SCFβ-TrCP ubiquitin ligase complex and exists as two closely related isoforms, β-TrCP1 and β-TrCP2. Under the influence of Wnt signaling, it binds and regulates the degradation of the proto-oncogene β-catenin (11). β-catenin has a dual role in the cell, serving both as a component of adherens junctions in the cytoplasm and as a transcriptional coregulator in the nucleus, modulating the function of the TCF/LEF transcription factors (35). The Wnt/β-catenin pathway plays key roles in development and tumorigenesis, and mutations in the system leading to the excessive accumulation of β-catenin have been identified at high frequency in human tumors (9, 35, 36).

Aberrant activation of the Ras pathway is one of the most common defects observed in human cancers (37). Over a decade of study has revealed multiple, subtle links between the Ras and Wnt/β-catenin pathways. The links are complex and remain poorly understood because they invoke both synergistic and antagonistic relationships (6). Indeed, Ras has been reported to suppress β-catenin levels but also to promote β-catenin transcription (31, 32). The net effect appears to be context-dependent. However, in vivo studies have confirmed that defects in the two pathways can synergize to promote cancer (3).

Here we show that Ras promotes the binding of NORE1A to β-TrCP1, the substrate recognition component of the SCFβ-TrCP ubiquitin ligase, and that this interaction promotes the degradation of β-catenin (Fig. 8). Because we identified NORE1A and β-TrCP1 in a yeast two hybrid interaction screen, this interaction is likely to be direct. The interaction of NORE1A with β-TrCP1 explains how Ras can negatively regulate β-catenin and how such regulation may be defective in tumor cells that have suffered inactivation of NORE1A. By using FTIs to inhibit the endogenous activated Ras in our NCI-H1299 cell system, we were able to show that Ras down-regulates endogenous β-catenin protein levels in the presence of NORE1A but enhances them in its absence. Therefore, the levels of NORE1A in a cell may play a major role in determining the net effect of Ras on β-catenin. However, it is not impossible that these experiments also impacted non-Ras farnesylated targets. Therefore, further experiments to examine the biological effects of the Ras/NORE1A/β-TrCP1 interaction may be warranted.

The mechanism by which NORE1A specifically stimulates SCFβ-TrCP via β-TrCP1 remains unclear. We hypothesize that NORE1A may be acting as a scaffold for other regulatory components such as kinases.

β-TrCP1 can act as a tumor suppressor (11), as expected, because it can serve as a negative regulator of β-catenin, but it has also been reported to exhibit oncogenic functions in some cellular environments (12, 13). This may be due to its effects on substrates in addition to β-catenin. These include a range of proteins involved in cell cycle regulation and transcriptional control, such as IκB (38, 39), NFκB (40), GLI2 (41, 42), REST (43, 44), ATF4 (45), CDC25A (46, 47), CDC25B (47), and Claspin (48, 49). It seems likely that mechanisms exist to target β-TrCP to particular substrates under particular conditions. NORE1A may be part of such a mechanism because it activates β-TrCP1 toward β-catenin but not toward IκB. Because we found that the ability of β-TrCP1 to suppress growth of tumor cells is heavily dependent upon the presence of NORE1A, it may be the NORE1A status of a cell that dictates whether or not β-TrCP1 is oncogenic or tumor-suppressive. It will be interesting to determine against which other substrates NORE1A activates β-TrCP1.

NORE1A is not the first member of the RASSF family to be identified as binding to β-TrCP1. A splice variant of the RASSF1A protein, RASSF1C, can also bind (50). However, unlike NORE1A, RASSF1C acts to somehow stabilize β-catenin protein levels and enhance β-catenin signaling. Perhaps it acts by competing with NORE1A for binding.

Another pathway with which RASSF family members have been associated is the Hippo pathway. This pathway is a major signaling mechanism involved in controlling organ size and apoptosis (51). The canonical Hippo signaling pathway involves a kinase cascade where MST kinases phosphorylate LATS kinases, which then act on the transcriptional coregulators YAP and TAZ (52). RASSF proteins such as NORE1A can bind and
activate the MST/Hippo kinases (18) and, therefore, may regulate the activity the Hippo pathway executors YAP and TAZ by phosphorylation. However, in addition to β-catenin, β-TrCP1 also binds and regulates the stability of YAP and TAZ (53). Moreover, β-catenin has been shown to bind to YAP and TAZ in a transcription complex (54). Therefore, the interaction of NORE1A with β-TrCP1 may allow NORE1A to invoke powerful non-canonical Hippo pathway regulation, which may also be controlled by Ras. This may prove to be a potent additional mechanism where the RASSF family proteins contribute to growth and survival control.

We identify a function for NORE1A acting as a Ras-regulated scaffold for β-TrCP1 that activates the ubiquitin ligase complex toward specific targets. These results may explain, mechanistically, many of the apparent contradictions in the relationship between the Ras and Wnt/β-catenin pathways.

REFERENCES
1. Malumbres, M., and Barbacid, M. (2003) RAS oncogenes: the first 30 years. Nat. Rev. Cancer 3, 459–465
2. Campbell, S. L., Khosravi-Far, R., Rossman, K. L., Clark, G. J., and Der, C. J. (1998) Increasing complexity of Ras signaling. Oncogene 17, 1395–1413
3. Pacheco-Pinedo, E. C., and Morrisey, E. E. (2011) Wnt and Kras signaling: dark siblings in lung cancer. Oncotarget 2, 569–574
4. Jang, J. W., Boxer, R. B., and Chodosh, L. A. (2006) Isoform-specific ras activation and oncogene dependence during MYC- and Wnt-induced mammary tumorigenesis. Mol. Cell. Biol. 26, 8109–8121
5. Jeong, W. J., Yoon, J., Park, J. C., Lee, S. H., Lee, S. H., Kadoval, S., Kim, H., Yoon, J. B., and Choi, K. Y. (2012) Ras stabilization through aberrant activation of Wnt/β-catenin signaling promotes intestinal tumorigenesis. Sci. Signal 5, ra30
6. Kim, S. E., Yoon, J. Y., Jeong, W. J., Jeon, S. H., Park, Y., Yoon, J. B., Park, Y. N., Kim, H., and Choi, K. Y. (2009) H-Ras is degraded by Wnt/β-catenin signaling via β-TrCP-mediated polyubiquitylation. J. Cell Sci. 122, 842–848
**Ras Regulates β-TrCP Activity via NORE1A**

7. Saño, M. S., Rempinski, D. R., Jr., Rustum, Y. M., and Azrak, R. G. (2010) Targeting the oncogenic protein β-catenin to enhance chemotherapy outcome against solid human cancers. *Mol. Cancer* 9, 310.

8. Orford, K., Crockett, C., Jensen, J. P., Weissman, A. M., and Byers, S. W. (1997) Serine phosphorylation-regulated ubiquitination and degradation of β-catenin. *J. Biol. Chem.* 272, 24735–24738.

9. Giles, R. H., van Es, J. H., and Clevers, H. (2003) Caught up in a Wnt storm: Wnt signaling in cancer. *Biochim. Biophys. Acta* 1653, 1–24.

10. Xue, M. X., Zhao, L., Deng, C., Yang, L., Wang, Y., Gao, T., Li, L., Lin, J., and Zhang, L. (2013) Curcumin suppresses proliferation and induces apoptosis of human hepatocellular carcinoma cells via the Wnt signaling pathway. *Int. J. Oncol.*

11. Liu, C., Kato, Y., Zhang, B., Do, V. M., Yankner, B. A., and He, X. (1999) β-TrCP couples β-catenin phosphorylation-degradation and regulates X-eaposis axis formation. *Proc. Natl. Acad. Sci. U.S.A.* 96, 6273–6278.

12. Karin, M., Cao, Y., Greten, F. R., and Li, Z. W. (2002) NF-κB in cancer: from innocent bystander to major culprit. *Nat. Rev. Cancer* 2, 301–310.

13. Richmond, A. (2002) NF-κB, chemokine gene transcription and tumour growth. *Nat. Rev. Immunol.* 2, 664–674.

14. Namely, I., van Vught, M. A., Smits, V. A., Meuleman, B., Perrasik, A., Medema, R. H., and Freire, R. (2006) Polo-like kinase-1 controls proteasome-dependent degradation of Claspin during checkpoint recovery. *Curr. Biol.* 16, 1950–1955.

15. Cox, A. D., and Der, C. J. (2003) The dark side of Ras: regulation of apoptosis. *Oncogene* 22, 8999–9006.

16. Donninger, H., Vos, M. D., and Clark, G. J. (2007) The RASSF1A tumor suppressor. *J. Cell Sci.* 120, 3163–3172.

17. Schmidt, L. C., Kato, Y., Zhang, Z., Do, V. M., Yankner, B. A., and He, X. (1999) RASSF5 (Ras association (RalGDS/AF-6) domain family member 5). *Nature Genet.*

18. Kolligs, F. T., Hu, G., Dang, C. V., and Fearon, E. R. (1999) Neoplastic transformation of RK3E by mutant Ras Regulates β-TrCP activity via NORE1A family members and their role in human tumourigenesis. *Biochim. Biophys. Acta* 1408, 58–85.

19. Chen, J., Lui, W. O., Vos, M. D., Clark, G. J., Takahashi, M., Schoumans, J., Khoo, S. K., Petillo, D., Lavery, T., Sugimura, J., Astuti, D., Zhang, C., Kagawa, S., Maher, E. R., Larsson, C., Alberts, A. S., Kanayama, H. O., and Fahs, R. T. (2003) The pro-apoptotic Ras effecter Nore1 may serve as a Ras-regulated tumor suppressor in the lung. *J. Biol. Chem.* 278, 21938–21943.

20. van der Weyden, L., and Adams, D. J. (2007) The Ras-association domain family (RAF51) and their role in human tumourigenesis. *Methods Enzymol.* 385, 395–412.

21. Clark, G. J., Cox, A. D., Graham, S. M., and Der, C. J. (1995) Biological assays for Ras transformation. *Methods Enzymol.* 255, 395–412.

22. Fiordalisi, J. J., Johnson, R. L., 2nd, Ulkü, A. S., Der, C. J., and Cox, A. D. (2001) Mammalian expression vectors for Ras family proteins: generation and use of expression constructs to analyze Ras family function. *Methods Enzymol.* 332, 3–36.

23. Vos, M. D., Ellis, C. A., Elam, C., Ulku, A. S., Taylor, B. J., and Clark, G. J. (2003) RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. *J. Biol. Chem.* 278, 28045–28051.

24. Schulman, B. A., Carrano, A. C., Jeffrey, P. D., Bowen, Z., Kinnucan, E. R., Finnin, M. S., Elledge, S. J., Harper, J. W., Pagano, M., and Pavletich, N. P. (2000) Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex. *Nature* 408, 381–386.

25. Ortiz-Vega, S., Khokhlatchev, A., Nedwidek, M., Zhang, X. F., Dammann, R., Pfeifer, G. P., and Avruch, J. (2002) The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. *Oncogene* 21, 1381–1390.

26. Biechele, T. L., Adams, A. M., and Moon, R. T. (2009) Transcription-based reporters of Wnt/β-catenin signaling. *Cold Spring Harbor protocols* 2009, pdb prot5223.
Ras Regulates β-TrCP Activity via NORE1A

tis, T., Sherman, N. E., and Pagano, M. (2006) SCFβTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol. Cell 23, 319–329

49. Mailand, N., Bekker-Jensen, S., Bartek, J., and Lukas, J. (2006) Destruction of Claspin by SCFβTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol. Cell 23, 307–318

50. Estrabaud, E., Lassot, I., Blot, G., Le Rouzic, E., Tanchou, V., Quemeneur, E., Daviet, L., Margottin-Goguet, F., and Benarous, R. (2007) RASSF1C, an isoform of the tumor suppressor RASSF1A, promotes the accumulation of β-catenin by interacting with βTrCP. Cancer Res. 67, 1054–1061

51. Zhao, B., Lei, Q. Y., and Guan, K. L. (2008) The Hippo-YAP pathway: new connections between regulation of organ size and cancer. Curr. Opin. Cell Biol. 20, 638–646

52. Zhao, B., Li, L., Lei, Q., and Guan, K. L. (2010) The Hippo-YAP pathway in organ size control and tumorigenesis: an updated version. Genes Dev. 24, 862–874

53. Liu, C. Y., Zha, Z. Y., Zhou, X., Zhang, H., Huang, W., Zhao, D., Li, T., Chan, S. W., Lim, C. J., Hong, W., Zhao, S., Xiong, Y., Lei, Q. Y., and Guan, K. L. (2010) The hippo tumor pathway promotes TAZ degradation by phosphorylating a phosphodegron and recruiting the SCFβ-TrCP E3 ligase. J. Biol. Chem. 285, 37159–37169

54. Konsavage, W. M., Jr., and Yochum, G. S. (2013) Intersection of Hippo/YAP and Wnt/β-catenin signaling pathways. Acta Biochim. Biophys. Sinica 45, 71–79